Literature DB >> 22899731

Lung cancer survival among black and white patients in an equal access health system.

Li Zheng1, Lindsey Enewold, Shelia H Zahm, Craig D Shriver, Jing Zhou, Aizen Marrogi, Katherine A McGlynn, Kangmin Zhu.   

Abstract

BACKGROUND: Racial disparities in lung cancer outcomes have been observed in the general population. However, it is unclear whether survival differences persist when patients have equal access to health care. Our objective was to determine if lung cancer survival differed among black and white patients in the U.S. Military Health System (MHS), an equal access health care system.
METHODS: The study subjects were 10,181 black and white patients identified through the Department of Defense's Automated Central Tumor Registry, who were 20 years old or more and diagnosed with lung cancer between 1990 and 2003. Racial differences in all-cause survival were examined using the Kaplan-Meier method and Cox proportional hazards regression models stratified by histology. For comparison, survival rates in the general population were calculated using Surveillance Epidemiology and End Results-9 data.
RESULTS: Analyses included 9,154 white and 1,027 black patients: 1,834 small cell lung cancers, 3,876 adenocarcinomas, 2,741 squamous cell carcinomas, and 1,730 large cell carcinomas. Although more favorable crude survival was observed among black patients than white patients with small cell lung cancer (P = 0.04), survival was similar between the two groups after covariate adjustment. Racial differences in survival were nonsignificant for adenocarcinomas, squamous cell carcinomas, and large cell carcinomas. Survival rates appeared to be better in the MHS than in the general population. CONCLUSIONS AND IMPACT: All-cause survival was similar among black and white lung cancer patients in the MHS. Providing equal access to health care may eliminate racial disparities in lung cancer survival while improving the outcome of all cases. 2012 AACR

Entities:  

Mesh:

Year:  2012        PMID: 22899731      PMCID: PMC4151240          DOI: 10.1158/1055-9965.EPI-12-0560

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  27 in total

1.  The influence of race, ethnicity, and individual socioeconomic factors on breast cancer stage at diagnosis.

Authors:  Paula M Lantz; Mahasin Mujahid; Kendra Schwartz; Nancy K Janz; Angela Fagerlin; Barbara Salem; Lihua Liu; Dennis Deapen; Steven J Katz
Journal:  Am J Public Health       Date:  2006-10-31       Impact factor: 9.308

2.  Association of insurance status and ethnicity with cancer stage at diagnosis for 12 cancer sites: a retrospective analysis.

Authors:  Michael T Halpern; Elizabeth M Ward; Alexandre L Pavluck; Nicole M Schrag; John Bian; Amy Y Chen
Journal:  Lancet Oncol       Date:  2008-02-20       Impact factor: 41.316

3.  Racial disparities and survival for nonsmall-cell lung cancer in a large cohort of black and white elderly patients.

Authors:  Dale Hardy; Rui Xia; Chih-Chin Liu; Janice N Cormier; Zhannat Nurgalieva; Xianglin L Du
Journal:  Cancer       Date:  2009-10-15       Impact factor: 6.860

4.  Underuse of surgical resection for localized, non-small cell lung cancer among whites and African Americans in South Carolina.

Authors:  Nestor F Esnaola; Mulugeta Gebregziabher; Kelly Knott; Chris Finney; Gerard A Silvestri; Carolyn E Reed; Marvella E Ford
Journal:  Ann Thorac Surg       Date:  2008-07       Impact factor: 4.330

5.  Association of insurance with cancer care utilization and outcomes.

Authors:  Elizabeth Ward; Michael Halpern; Nicole Schrag; Vilma Cokkinides; Carol DeSantis; Priti Bandi; Rebecca Siegel; Andrew Stewart; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2007-12-20       Impact factor: 508.702

6.  Impact of race on outcomes of patients with non-small cell lung cancer.

Authors:  Ayesha S Bryant; Robert James Cerfolio
Journal:  J Thorac Oncol       Date:  2008-07       Impact factor: 15.609

7.  Low socioeconomic status is a poor prognostic factor for survival in stage I nonsmall cell lung cancer and is independent of surgical treatment, race, and marital status.

Authors:  S-H Ignatius Ou; Jason A Zell; Argyrios Ziogas; Hoda Anton-Culver
Journal:  Cancer       Date:  2008-05-01       Impact factor: 6.860

8.  Parity and disparity in first course treatment of invasive breast cancer.

Authors:  Mary Jo Lund; Otis P Brawley; Kevin C Ward; John L Young; Sheryl S G Gabram; J William Eley
Journal:  Breast Cancer Res Treat       Date:  2007-07-21       Impact factor: 4.872

9.  Racial disparities and treatment trends in a large cohort of elderly black and white patients with nonsmall cell lung cancer.

Authors:  Dale Hardy; Chih-Chin Liu; Rui Xia; Janice N Cormier; Wenyaw Chan; Arica White; Keith Burau; Xianglin L Du
Journal:  Cancer       Date:  2009-05-15       Impact factor: 6.860

10.  Racial disparities in cancer survival among randomized clinical trials patients of the Southwest Oncology Group.

Authors:  Kathy S Albain; Joseph M Unger; John J Crowley; Charles A Coltman; Dawn L Hershman
Journal:  J Natl Cancer Inst       Date:  2009-07-07       Impact factor: 13.506

View more
  25 in total

1.  A Prognostic Model to Predict Mortality among Non-Small-Cell Lung Cancer Patients in the U.S. Military Health System.

Authors:  Jie Lin; Corey A Carter; Katherine A McGlynn; Shelia H Zahm; Joel A Nations; William F Anderson; Craig D Shriver; Kangmin Zhu
Journal:  J Thorac Oncol       Date:  2015-12       Impact factor: 15.609

2.  Racial Disparities in Lung Cancer Survival: The Contribution of Stage, Treatment, and Ancestry.

Authors:  Carissa C Jones; Sarah Fletcher Mercaldo; Jeffrey D Blume; Angela S Wenzlaff; Ann G Schwartz; Heidi Chen; Stephen A Deppen; William S Bush; Dana C Crawford; Stephen J Chanock; William J Blot; Eric L Grogan; Melinda C Aldrich
Journal:  J Thorac Oncol       Date:  2018-06-06       Impact factor: 15.609

3.  Overall and recurrence-free survival among black and white bladder cancer patients in an equal-access health system.

Authors:  Jill K Schinkel; Stephanie Shao; Shelia H Zahm; Katherine A McGlynn; Craig D Shriver; Kangmin Zhu
Journal:  Cancer Epidemiol       Date:  2016-05-06       Impact factor: 2.984

4.  Stage-adjusted lung cancer survival does not differ between low-income Blacks and Whites.

Authors:  Melinda C Aldrich; Eric L Grogan; Heather M Munro; Lisa B Signorello; William J Blot
Journal:  J Thorac Oncol       Date:  2013-10       Impact factor: 15.609

5.  Relationship between West African ancestry with lung cancer risk and survival in African Americans.

Authors:  Khadijah A Mitchell; Ebony Shah; Elise D Bowman; Adriana Zingone; Noah Nichols; Sharon R Pine; Rick A Kittles; Bríd M Ryan
Journal:  Cancer Causes Control       Date:  2019-08-29       Impact factor: 2.506

6.  Lung Adenocarcinoma Survival in EGFR-Mutated African-Caribbean Patients: A Multicenter Study in the French West Indies.

Authors:  Nicolas Leduc; Vincent Atallah; Moustapha Agossou; Vincent Vinh-Hung; Mathieu Orre; Paul Sargos; Vincent Molinie
Journal:  Target Oncol       Date:  2017-10       Impact factor: 4.493

Review 7.  Lung cancer health disparities.

Authors:  Bríd M Ryan
Journal:  Carcinogenesis       Date:  2018-05-28       Impact factor: 4.944

Review 8.  Disparities in Lung Cancer Screening: A Review.

Authors:  Diane N Haddad; Kim L Sandler; Louise M Henderson; M Patricia Rivera; Melinda C Aldrich
Journal:  Ann Am Thorac Soc       Date:  2020-04

9.  The Military Health Care System May Have the Potential to Prevent Health Care Disparities.

Authors:  Bosny J Pierre-Louis; Angelo D Moore; Jill B Hamilton
Journal:  J Racial Ethn Health Disparities       Date:  2014-12-06

10.  Effect of Prophylactic Cranial Irradiation on Overall Survival in Metastatic Small-Cell Lung Cancer: A Propensity Score-Matched Analysis.

Authors:  Sonam Sharma; Matthew T McMillan; Abigail Doucette; Roger B Cohen; Abigail Berman; William Levin; Charles B Simone; Jacob Shabason
Journal:  Clin Lung Cancer       Date:  2017-12-14       Impact factor: 4.785

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.